South Korea's drug watchdog to review U.S. Tylenol claim
SEOUL, Sept 24 (Reuters) - South Korea's drug watchdog said on Tuesday it would seek information from relevant companies after U.S. President Donald Trump linked the use of Tylenol by pregnant women to autism, a claim that is unsupported by scientific evidence.
The drug regulator said it would review the opinions and documents provided by the companies.
On Monday, Trump also linked autism to childhood vaccine use.
"Since the U.S. government’s announcement contained little substance, we have no additional comments," South Korea's food and drug safety ministry said on Wednesday.
"However, we plan to request relevant papers and data from paracetamol importers and manufacturers."
After Trump linked paracetamol to autism, international health agencies reaffirmed it was safe to use during pregnancy.
The World Health Organization said there was no conclusive scientific evidence linking paracetamol use during pregnancy to autism.
The European Medicines Agency said available evidence had found no such link and advised use of the lowest effective doses of the drug according to the frequency needed.
Related Articles
U.S. August PCE: Inflation Remains the Market's Greatest Risk
Our baseline forecast anticipates sustained asset price increases. However, if inflation surpasses market expectations in the coming months, it could hinder further rate cuts and pose the greatest risk to financial markets.
Memory Giant Micron Delivers Stellar Q4 FY2025 with Explosive DRAM and HBM Growth
TradingKey - Micron Technology, Inc. (NASDAQ: MU) delivered a stellar Q4 FY2025 earnings report, exceeding expectations on revenue, earnings, and margins. The company reported total revenue of $11.32 billion, up 46% YoY and 22% sequentially, surpassing the consensus forecast of $11.1 billion.
Fed Rate Cuts: Will the Russell 2000 Outperform the S&P 500?
TradingKey - On 17 September, the Federal Reserve cut interest rates by 25 basis points, marking the official restart of the rate-cutting cycle. In theory, small-cap stocks, compared to large-cap stocks, benefit more from Fed rate cuts. This is because they are more reliant on external financing...
Broadcom Q3 FY2025 Earnings Review: AI Surge and VMware Synergy Fuel Record Performance
TradingKey - Broadcom Inc. (NASDAQ: AVGO) delivered a strong fiscal Q3 2025, with results driven by AI networking strength and continued VMware integration. Revenue and EPS both topped expectations, reinforcing the company’s role as an essential player in the AI infrastructure buildout.
Powell's Jackson Hole Speech: For U.S. Stocks, Hawk or Dove Signal Could Be a Lose-Lose?
TradingKey - As U.S. inflation and labor market data show signs of rebalancing, Treasury traders and Wall Street banks have largely priced in a rate cut at the September FOMC meeting — the first of 2025. Yet both a more dovish-than-expected tone and a potential surprise hawkish signal from Fed Chair
